AFT Pharmaceuticals Limited (AFT) investor relations material

Opening remarks and agenda

• Meeting opened with formalities, introduction of directors, auditors, and senior management, and confirmation of quorum.

• Chair and Managing Director delivered opening addresses, followed by discussion, resolutions, general business, and meeting close.

• Agenda included presentations, formal business, resolutions, and opportunities for shareholder questions.

Financial performance review

• Achieved record results: revenue up 22% to NZD 254.7 million, operating profit up 39% to NZD 24.4 million, and net profit after tax at NZD 14.1 million.

• FY26 total sales reached $254.7M, up 22% year-on-year, with operating profit at $24.4M, exceeding guidance.

• Group revenue and profit growth driven by strong performance in Australia (revenue up 19%), New Zealand (revenue up 11%), Asia (revenue up 41%), and international markets (revenue up 66%).

• Products now sold in 87 countries, up from 80 last year.

• Net debt increased to NZD 38.6 million, reflecting higher inventory and new product licenses, but remains within target range.

Board and executive committee updates

• Marree Atkinson retired by rotation and offered herself for re-election, with full board support.

• Malcolm Tubby, previous CFO, retired; Stuart Houliston appointed as new CFO.

• Chair David Flacks announced intention to retire within 12 months, after 12 years of service.

• Board includes Managing Director/CEO, Executive Director/Chief of Staff, and three Independent Directors.